- Trial phase
- Phase 1
- Time to market
- ARV-027 is in Phase 1; assuming successful development, a potential approval is likely several years away (Phase 3 and regulatory review would follow Phase 1/2).
- Why 4/10
- The next catalyst is initial Phase 1 healthy-volunteer data, guided for the first half of 2027 (a broad window, not a precise date). This is early-stage proof-of-mechanism data, not a pivotal readout or PDUFA. ARV-027 is one of several pipeline programs at Arvinas (alongside ARV-393, ARV-102, ARV-6723, and the approved vepdegestrant), so it is not the sole or lead value driver. Impact score of 4 reflects an early-stage drug with a non-pivotal catalyst 2-8 months out at a company with multiple other programs.
The next catalyst for ARV-027 is initial Phase 1 healthy-volunteer data, expected in the first half of 2027. Positive proof-of-mechanism (muscle androgen-receptor degradation) would validate the PROTAC approach in SBMA and could lift the stock; negative safety or PK results would be a setback for the program. The stock also has nearer-term catalysts in ARV-393 (ASH data December 2026) and ARV-102 updates, so ARV-027 is not the only binary event on the horizon.
Price Chart
Executive Summary
ARV-027 is an investigational oral PROTAC degrader from Arvinas (NASDAQ: ARVN) designed to treat Spinal and Bulbar Muscular Atrophy (SBMA, or Kennedy's disease), a rare X-linked neuromuscular disorder with no approved disease-modifying therapy. The drug targets and eliminates the toxic mutant androgen receptor protein in skeletal muscle. A Phase 1 first-in-human trial (EU CT 2025-523469-79-00) began enrolling in January 2026 in the Netherlands. Arvinas guided on its Q3 2026 earnings call (November 3, 2026) that initial healthy-volunteer data is expected in the first half of 2027, with patient dosing to begin in the same period. ARV-027 is one of several pipeline assets at Arvinas, which also has the FDA-approved vepdegestrant (Veppanu, partnered with Pfizer) and other Phase 1 programs (ARV-393, ARV-102, ARV-6723). A key competitor, AnnJi Pharmaceutical's AJ201 (rosolutamide), has already advanced to Phase 3 for SBMA. Arvinas had $558.9M in cash as of Q3 2026 with runway into H2 2028.
How It Works
ARV-027 is an oral pill that uses Arvinas' PROTAC technology to hijack the cell's natural garbage-disposal system (the ubiquitin-proteasome pathway) to specifically find and destroy the mutant androgen receptor protein that causes Kennedy's disease (SBMA). It is designed to stay in the periphery (not cross into the brain) and work primarily in skeletal muscle, where the toxic protein buildup drives muscle weakness and wasting.
Trial Status
A first-in-human, single-center, randomized, double-blind, placebo-controlled Phase 1 study (EU CT 2025-523469-79-00) is ongoing and recruiting in the Netherlands. The trial has three parts: single ascending dose (SAD) and multiple ascending dose (MAD) in healthy volunteers, followed by a multiple-dose portion in SBMA patients. Enrollment in the MAD cohort with healthy volunteers was initiated as of Q3 2026. Initial healthy-volunteer data is expected in the first half of 2027, with patient dosing to begin in the same period.
The Two-Sided Case
Upcoming Catalysts
- Initial Phase 1 healthy-volunteer data for ARV-027 (H1 2027) -- proof-of-mechanism muscle androgen receptor degradation readout
- Initiation of patient (SBMA) dosing in the Phase 1 trial (H1 2027)
- ASH 2026 presentation of ARV-393 Phase 1 data (December 2026) -- a separate pipeline catalyst for Arvinas
Source Filing
The SecBot filing or press-release report that triggered this drug report:
Arvinas Inc. PRESS-RELEASE ARVN ·Originating report